Emerging Innovative Therapeutic Approaches Leveraging Cyclin-Dependent Kinase Inhibitors to Treat Advanced Breast Cancer

Marcelo Cruz*, Tomás Reinert, Massimo Cristofanilli

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

6 Scopus citations

Abstract

Estrogen receptor-positive (ER+) tumors represent the most common form of breast cancer. Although endocrine therapy (ET) results in benefit for the majority of these patients, disease progression invariably occurs. The discovery of the relation between cyclin-dependent kinases (CDKs) and the ER pathways is one of the major advances in unveiling mechanisms of resistance to ET. In this article we review the role of CDK4/6 inhibitors in ER + breast cancer patients.

Original languageEnglish (US)
Pages (from-to)1009-1019
Number of pages11
JournalClinical pharmacology and therapeutics
Volume103
Issue number6
DOIs
StatePublished - Jun 2018

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Emerging Innovative Therapeutic Approaches Leveraging Cyclin-Dependent Kinase Inhibitors to Treat Advanced Breast Cancer'. Together they form a unique fingerprint.

Cite this